Alpha 2.0
Login Register
» Articles » PMID: 39651392

A Spectacular Effect of Tocilizumab in Takayasu Arteritis

Overview
Journal Eur J Case Rep Intern Med
Specialty General Medicine
Date 2024 Dec 9
PMID 39651392
Authors
Fatma Said
Ines Naceur
Tayssir Ben Achour
Maysam Jridi
Monia Smiti
Affiliations
Soon will be listed here.
Abstract

Background: Anti-interleukin-6 receptors (anti-IL-6R) have been a promising new therapeutic alternative in the treatment of Takayasu arteritis.

Case Description: We report the case of a 34-year-old patient with Takayasu arteritis diagnosed in 2017. While she was on corticosteroid and methotrexate, the patient presented twice with clinical and radiological signs of activity, requiring an increase of corticosteroid dose and an increase in the methotrexate dose to 20 mg/week. Anti-IL-6R infusions were indicated. At the end of the fifth infusion, the patient was totally asymptomatic: she no longer experienced episodes of syncope or amnesia.

Conclusion: Our case perfectly illustrates the effectiveness of anti-IL-6R in the treatment of Takayasu arteritis, especially in its refractory form.

Learning Points: Takayasu arteritis may have a significant functional impact that affects quality of life.Tocilizumab is a very interesting therapeutic alternative in the refractory form of Takayasu arteritis.

References
1.
Ponte C, Agueda A, Luqmani R . Clinical features and structured clinical evaluation of vasculitis. Best Pract Res Clin Rheumatol. 2018; 32(1):31-51. DOI: 10.1016/j.berh.2018.10.001. View
2.
Misra D, Rathore U, Patro P, Agarwal V, Sharma A . Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol. 2021; 40(11):4391-4416. PMC: 8087890. DOI: 10.1007/s10067-021-05743-2. View
3.
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S . Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2017; 77(3):348-354. PMC: 5867398. DOI: 10.1136/annrheumdis-2017-211878. View
4.
Kang L, Liu Y, Luo Z, Zhou Y, Chen B, Yin G . Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis. Front Immunol. 2023; 14:1084558. PMC: 9945188. DOI: 10.3389/fimmu.2023.1084558. View
5.
Misra D, Singh K, Rathore U, Patro P, Tomelleri A, Campochiaro C . The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis. Autoimmun Rev. 2023; 22(3):103275. DOI: 10.1016/j.autrev.2023.103275. View